D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Significance: PD-L1 is well known as an immune checkpoint molecule, which suppresses immune surveillance through binding to its receptor PD-1. Intracellular PD-L1 can also protect messenger RNAs of several DNA damage repair–related genes from degradation and enhance tumor resistance to DNA-damaging therapy. Triple-negative breast cancer (TNBC) has the worst prognosis and highest risk of distant relapse in breast cancer and shows resistance to immunotherapy and radiotherapy. In this study, we found that D-mannose can promote the degradation of PD-L1 and significantly enhance immunotherapy and radiotherapy of TNBC. Since TNBC treatment is still a clinical challenge, our findings provide strategies to enhance the therapeutic efficacy of TNBC and may have clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Immune checkpoint blockade therapy has been a focus of cancer research and treatment in recent years (8).”
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“6 and 7).”
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Global view of human protein glycosylation pathways and functions
Schjoldager, K. T., Narimatsu, Y., Joshi, H. J., & Clausen, H. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00294-x · Cited by 1,309 · cited 1×
“All N-glycans share a common core sequence and are further clas-sified into three types: high D-mannose, hybrid, and complex glycans (14, 15).”
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793 · cited 1×
“Ubiquitylation (29–32) and pal-mitoylation (33, 34) also regulate PD-L1 stability.”
Self-citationMetformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Effect of glycosylation on protein folding: A close look at thermodynamic stabilization
Shental-Bechor, D., & Levy, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801340105 · Cited by 618
Role of Immunotherapy in Triple-Negative Breast Cancer
Keenan, T. E., & Tolaney, S. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7554 · Cited by 606
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Yao, H., Lan, J., Li, C., Shi, H., Brosseau, J.-P., Wang, H., Lu, H., Fang, C., Zhang, Y., Liang, L., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0375-6 · Cited by 568
Mannose impairs tumour growth and enhances chemotherapy
Gonzalez, P. S., O’Prey, J., Cardaci, S., Barthet, V. J. A., Sakamaki, J.-I., Beaumatin, F., Roseweir, A., Gay, D. M., Mackay, G., Malviya, G., et al. (2018) · Nature · doi:10.1038/s41586-018-0729-3 · Cited by 428
HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
Wang, H., Yao, H., Li, C., Shi, H., Lan, J., Li, Z., Zhang, Y., Liang, L., Fang, J.-Y., & Xu, J. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0161-x · Cited by 325
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yang, Y., Hsu, J.-M., Sun, L., Chan, L.-C., Li, C.-W., Hsu, J. L., Wei, Y., Xia, W., Hou, J., Qiu, Y., et al. (2019) · Cell Research · doi:10.1038/s41422-018-0124-5 · Cited by 278 · cited 1×
“Ubiquitylation (29–32) and pal-mitoylation (33, 34) also regulate PD-L1 stability.”
Self-citationN-linked glycosylation and homeostasis of the endoplasmic reticulum
Cherepanova, N., Shrimal, S., & Gilmore, R. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.03.021 · Cited by 269
Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., Yin, P., Yuan, J., Pei, H., Li, H., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.04.005 · Cited by 263
Mannose metabolism: More than meets the eye
Sharma, V., Ichikawa, M., & Freeze, H. H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.021 · Cited by 238 · cited 2×
“Once taken into cells, D-mannose is phosphorylated by hexokinase (HK) and produces mannose-6-phosphate (M6P), which can be directed into glycolysis or glycosylation pathway (20).”
D-mannose induces regulatory T cells and suppresses immunopathology
Zhang, D., Chia, C., Jiao, X., Jin, W., Kasagi, S., Wu, R., Konkel, J. E., Nakatsukasa, H., Zanvit, P., Goldberg, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4375 · Cited by 236
β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
Du, L., Lee, J.-H., Jiang, H., Wang, C., Wang, S., Zheng, Z., Shao, F., Xu, D., Xia, Y., Li, J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191115 · Cited by 231
D-mannose suppresses macrophage IL-1β production
Torretta, S., Scagliola, A., Ricci, L., Mainini, F., Di Marco, S., Cuccovillo, I., Kajaste-Rudnitski, A., Sumpton, D., Ryan, K. M., & Cardaci, S. (2020) · Nature Communications · doi:10.1038/s41467-020-20164-6 · Cited by 224
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y.-N., Lee, H.-H., Hsu, J. L., Yu, D., & Hung, M.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 192
Huang, Y., Zhang, H.-L., Li, Z.-L., Du, T., Chen, Y.-H., Wang, Y., Ni, H.-H., Zhang, K.-M., Mai, J., Hu, B.-X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22618-x · Cited by 183
Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies
He, M. Y., Rancoule, C., Rehailia-Blanchard, A., Espenel, S., Trone, J.-C., Bernichon, E., Guillaume, E., Vallard, A., & Magné, N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.004 · Cited by 151
Immunotherapy in triple-negative breast cancer
Katz, H., & Alsharedi, M. F. (2017) · Medical Oncology · doi:10.1007/s12032-017-1071-6 · Cited by 132 · cited 1×
“…(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and accounts for ∼ 15 to 20% of all breast cancer cases (2, 3), has the worst prognosis compared to other subtypes, and the 5-y survival rate for these women if they do not present with metastatic disease is…”
Shao, B., Li, C.-W., Lim, S., Sun, L., Lai, Y., Hou, J., Liu, C., Chang, C.-W. M., Qiu, Y., Hsu, J.-M., et al. (2018) · Europe PMC (PubMed Central) · Cited by 82
Immunotherapy in Triple-Negative Breast Cancer
Emens, L. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000497 · Cited by 81 · cited 1×
“Currently, several clinical trials of anti–PD-L1 treatment in TNBC are showing encouraging and positive responses (35, 36).”
Mannose: Good player and assister in pharmacotherapy
Wei, Z., Huang, L., Cui, L., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110420 · Cited by 65
Sharma, V., & Freeze, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.194241 · Cited by 60
d -mannose suppresses oxidative response and blocks phagocytosis in experimental neuroinflammation
Wang, J., Motlagh, N. J., Wang, C., Wojtkiewicz, G. R., Schmidt, S., Chau, C., Narsimhan, R. P., Kuellenberg, E. G., Zhu, C., Linnoila, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107663118 · Cited by 47
Cited by
A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
Shen, W., Pei, P., Zhang, C., Li, J., Han, X., Liu, T., Shi, X., Su, Z., Han, G., Hu, L., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c08875 · Cited by 165
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S. (2023) · MedComm · doi:10.1002/mco2.288 · Cited by 62
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment
Sarlak, S., Pagès, G., & Luciano, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102939 · Cited by 19
“Novel approaches, including D-mannose treatment, have shown potential in enhancing immunotherapy efficacy by promoting PD-L1 degradation [80,81].”
Metadata
- Authors
- Zhang, R., Yang, Y., Dong, W., Lin, M., He, J., Zhang, X., Tian, T., Yang, Y., Chen, K., Lei, Q.-Y., Zhang, S., Xu, Y., & Lv, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2022-02-18
- Volume
- 119
- Issue
- 8
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W4213108994
- Cited by
- 229
- References
- 40
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.